Phagemid Vector

Abstract

The invention provides hybrid and recombinant phagemid vectors for expressing a transgene in a target cell transduced with the vector. A recombinant phagemid particle comprises at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome. The invention extends to the use of such phagemid expression systems as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques. The invention extends to in vitro, in vivo or in situ methods for producing viral vectors, such as recombinant adeno-associated viruses (rAAV) or lentivirus vectors (rLV), and to genetic constructs used in such methods.

Claims

1. A recombinant phagemid particle for expressing a transgene in a target cell transduced with the particle, the phagemid particle comprising at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome.

2. A particle according to claim 1, wherein the genome of the recombinant phagemid particle comprises a packaging signal for enabling replication of the phagemid genome into single-stranded DNA, which can subsequently be packaged into the phagemid particle inside a prokaryotic host.

3. A particle according to claim 2, wherein the packaging signal comprises an origin of replication, optionally an F1 ori.

4. A particle according to any preceding claim, wherein the genome of the recombinant phagemid particle comprises an origin of replication for enabling replication of double-stranded vector inside a prokaryotic host, optionally a pUC ori.

5. A particle according to any preceding claim, wherein the genome of the recombinant phagemid particle comprises one or more DNA sequence, which favours targeted integration into a host genome.

6. A particle according to any preceding claim, wherein the at least one transgene expression cassette comprises a viral transgene expression cassette.

7. A particle according to any preceding claim, wherein the at least one transgene expression cassette comprises a mammalian viral transgene expression cassette.

8. A particle according to any preceding claim, wherein the at least one transgene expression cassette comprises a lentivirus transgene expression cassette.

9. A particle according to any preceding claim, wherein the at least one transgene expression cassette comprises an adeno-associated virus (AAV) transgene expression cassette.

10. A particle according to any preceding claim, wherein the transgene expression cassette comprises a nucleic acid encoding an agent, which has therapeutic or industrial utility in the target cell or tissue.

11. A particle according to claim 10, wherein the nucleic acid is DNA, genomic DNA, cDNA, RNA, antisense RNA or shRNA.

12. A particle according to claim 10 or claim 11, wherein the agent encoded by the nucleic acid is polypeptide or protein.

13. A particle according to any preceding claim, wherein the transgene expression cassette comprises one or more functional elements required for expression of the nucleic acid in the target cell selected from the groups consisting of: a promoter, nucleic acid for encoding a polyA tail attachable to the expressed agent, left and/or right Inverted Terminal Repeat sequences (ITRs).

14. A particle according to any preceding claim, wherein the recombinant phagemid particle comprises one or more capsid minor coat protein, optionally wherein the recombinant phagemid particle comprises a pIII capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the particle to the target cell.

15. A particle according to any preceding claim, wherein the recombinant phagemid particle comprises one or more capsid major coat protein, optionally wherein the recombinant phagemid particle comprises at least one pVIII capsid major coat protein that is configured to display a foreign peptide thereon.

16. A particle according to any preceding claim, wherein the recombinant phagemid particle is combined with a cationic polymer to form a complex having a net positive charge, optionally wherein the cationic polymer is selected from a group consisting of: chitosan; poly-D-lysine (PDL); diethylaminoethyl (DEAE); diethylaminoethyl-dextran (DEAE.DEX); polyethyleneimine (PEI); polybrene; protamine sulphate; and a cationic lipid.

17. A particle according to any preceding claim, wherein the genome of the recombinant phagemid particle lacks at least 60%, 70%, or at least 80% of the bacteriophage genome from which it is derived.

18. A particle according to any preceding claim, wherein the genome of the recombinant phagemid particle lacks at least 90%, 95%, or at least 99% of the bacteriophage genome from which it is derived.

19. A particle according to any preceding claim, wherein the phagemid particle lacks bacteriophage structural genes in its genome required for the formation, packaging or extrusion of the particle from a prokaryotic host, preferably structural genes which encode the capsid proteins.

20. A system for producing a recombinant phagemid particle from a prokaryotic host, the system comprising: (i) a first vector configured to persist inside a prokaryotic host, and comprising at least one transgene expression cassette, and a packaging signal for enabling replication of the vector into single-stranded DNA; and (ii) a second vector comprising nucleic acid encoding structural proteins required for packaging the single-stranded DNA, resulting in the formation and extrusion of a recombinant phagemid particle from the prokaryotic host.

21. A system according to claim 20, wherein the system is used to produce the recombinant phagemid particle according to any one of claims 1-19.

22. A system according to either claim 20 or claim 21, wherein the first vector comprises the genome of the recombinant phagemid particle.

23. A system according to any one of claims 20-22, wherein the second vector is a bacteriophage engineered specifically for rescuing the phagemid particles carrying the first vector from the prokaryotic host.

24. A system according to any one of claims 20-23, wherein the second vector is replication-defective.

25. A system according to any one of claims 20-24, wherein the second vector comprises a disrupted packaging signal, which significantly deters its ability to package itself into phage particles.

26. A system according to any one of claims 20-25, wherein the second vector comprises a disrupted origin of replication.

27. A system according to claims 26, wherein the disrupted origin of replication is a medium copy number origin, optionally p15a, or a low copy number origin, optionally a pMB1.

28. A system according to any one of claims 20-27, wherein the second vector comprises a first nucleic acid sequence encoding a pIII capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the recombinant phagemid particle to a target cell.

29. A system according to any one of claims 20-28, wherein the genome of the second vector comprises the RGD4C targeting peptide (CDCRGDCFCSEQ ID No: 7).

30. A system according to any one of claims 20-29, wherein the second vector comprises a second nucleic acid sequence encoding at least one pVIII capsid major coat protein that is configured to display a foreign peptide thereon.

31. A system according to any one of claims 20-30, wherein the first vector is a member of the Retroviridae family, or of the Orthoretrovirinae Sub-family.

32. A system according to any one of claims 20-31, wherein the first vector is a member of the Lentivirus genus.

33. A system according to any one of claims 20-32, wherein the first vector is a member of the Parvoviridae family or sub-family, preferably adeno-associated virus species.

34. A method for producing a recombinant phagemid particle from a prokaryotic host, the method comprising: (i) introducing, into a prokaryotic host cell, a first vector configured to persist inside the prokaryotic host, and comprising at least one transgene expression cassette, and a packaging signal for enabling replication of the vector into single-stranded DNA; (ii) introducing, into the host, a helper phage comprising nucleic acid encoding bacteriophage structural proteins; and (iii) culturing the host under conditions which result in the single-stranded DNA being packaged by the structural proteins to form and extrude a recombinant phagemid particle from the prokaryotic host.

35. A method for producing a recombinant phagemid particle from a prokaryotic host, the method comprising: (i) introducing into a prokaryotic host cell: (a) a first vector configured to persist inside the prokaryotic host, and comprising at least one transgene expression cassette, and a packaging signal for enabling replication of the vector into single-stranded DNA, and (b) a second vector comprising nucleic acid encoding structural proteins required for packaging the single-stranded DNA; and (ii) culturing the host under conditions which result in the single-stranded DNA being packaged by the structural proteins to form and extrude a recombinant phagemid particle from the prokaryotic host.

36. Use of a helper phage comprising nucleic acid encoding viral vector structural proteins to produce the recombinant phagemid particle according to any one of claims 1-19 from a prokaryotic host.

37. Use of the recombinant phagemid particle according to any one of claims 1-19, or the system according to any one of claims 20-33, to produce a recombinant viral vector comprising or derived from the viral genome within the genome of the phagemid particle.

38. A method for producing recombinant viral vector, the method comprising introducing into, a eukaryotic host cell, the recombinant phagemid particle according to any one of claims 1-19, or the system according to any one of claims 20-33, and allowing the host cell to produce recombinant viral vector.

39. Use according to claim 37 or a method according to claim 38, wherein the recombinant virus product is a recombinant mammalian virus.

40. Use or method according to any one of claims 37-39, wherein the recombinant virus product is rAAV.

41. Use or method according to any one of claims 37-40, wherein the recombinant virus product is recombinant lentivirus.

42. Use or method according to any one of claims 38-41, wherein the phagemid particle or the system is used in cis and/or trans together with the delivery and/or presence of other genetic elements required for the production of mammalian viruses, as determined by the phagemid particle's genome, inside the eukaryotic host cell.

43. Use or method according to any one of claims 38-42, wherein the eukaryotic host cell is mammalian, optionally the host cell comprises or is derived from Human Embryonic Kidney Cells (HEK293), Spodoptera frugiperda pupal ovarian tissue (Sf9), insect cells, or Chinese Hamster Ovary (CHO).

44. Use or method according to any one of claims 38-43, wherein the host cell is transformed with one or more phagemid particle genome carrying genes selected from the group consisting of: rAAV, lentivirus, capsid, replication, helper protein encoding genes, and any other genes required for the expression and packaging of mammalian viruses.

45. Use or method according to any one of claims 38-44, wherein the rAAV gene is carried by the recombinant phagemid viral particle, and the adenohelper and rep-cap genes are carried on separate vectors, or are integrated into the eukaryotic host genome.

46. Use or method according to any one of claims 38-45, wherein rAAV, rep-cap and adenohelper genes are carried on a single vector.

47. A recombinant vector comprising comprising rAAV, rep-cap and adenohelper genes.

48. A recombinant phagemid particle comprising the vector according to claim 47.

49. Use of the vector according to claim 47 or the particle according to claim 48, to produce a recombinant AAV viral vector comprising or derived from the viral genome of the phagemid particle.

50. A method for producing recombinant AAV viral vector, the method comprising introducing into, a eukaryotic host cell, the vector according to claim 47 or the particle according to claim 48, and allowing the host cell to produce recombinant viral vector.

51. Use according to claim 49 or the method according to claim 50, wherein when introduced into the same eukaryotic host cell, the rep-cap and adenohelper genes on the vector behave as trans-acting or cis-acting or a combination of both elements that facilitate packaging of the rAAV genome in the AAV virus capsid, in the context of rAAV production.

52. Use or method according to any one of claims 49-51, wherein the method is carried out in vivo, in vitro, ex vivo, or in situ.

53. Use or method according to any one of claims 49-52, wherein the recombinant phagemid particle comprises a targeting moiety for the target eukaryotic cell that is the designated eukaryotic host.

54. Use or method according to claim 53, wherein the designated eukaryotic host cell type is a diseased cell.

55. Use or method according to claim 54, wherein the diseased cell is a malignant or benign tumour.

56. A host cell comprising the first and/or second vector as defined in any one of claims 20-33.

57. A host cell according to claim 56, wherein the host cell is prokaryotic, more preferably a bacterial cell.

58. The recombinant phagemid particle according to any one of claims 1-19, or the system according to any one of claims 20-33, for use as an experimental research tool, optionally ex vivo or in vitro use.

59. The recombinant phagemid particle according to any one of claims 1-19, or the system according to any one of claims 20-33, for use in therapy or diagnosis.

60. The recombinant phagemid particle according to any one of claims 1-19, or the system according to any one of claims 20-33, for use in a gene therapy technique.

61. The recombinant phagemid particle or the system, for use according to either claim 59 or claim 60, wherein the gene therapy technique is used to treat, prevent or ameliorate cancer.

62. A vaccine comprising the recombinant phagemid particle according to any one of claims 1-19, or the system any one of claims 20-33.

63. The recombinant phagemid particle according to any one of claims 1-19, or the system any one of claims 20-33, for use in vaccine delivery to a subject.

64. A vaccine according to claim 62, or the use of claim 63, wherein the vaccine is a peptide vaccine or a DNA vaccine.

65. The recombinant phagemid particle according to any one of claims 1-19, or the system any one of claims 20-33, for use in delivering and targeting a foreign antigen to a tumour in a vaccinated subject.

66. Use of the recombinant phagemid particle according to any one of claims 1-19, or the system any one of claims 20-33, in a genetic-molecular imaging technique.

67. A pharmaceutical composition comprising the recombinant phagemid particle according to any one of claims 1-19, or the system any one of claims 20-33, and a pharmaceutically acceptable vehicle.

68. A process for making the pharmaceutical composition according to claim 67, the process comprising contacting a therapeutically effective amount of the recombinant phagemid particle according to any one of claims 1-19, or the system any one of claims 20-33, and a pharmaceutically acceptable vehicle.

Description

[0130] For a better understanding of the invention, and to show how embodiments of the same may be carried into effect, reference will now be made, by way of example, to the accompanying Figures, in which:

[0131] FIG. 1 is a table showing features of the phagemid-AAV (PAAV) virus particle according to the invention compared to prior art AAVP virus particles;

[0132] FIG. 2 shows schematic illustrations of embodiments of a Helper Phage and a Phagemid genome (PAAV) according to the invention, and a phagemid-AAV (PAAV) particle that is created by the Helper and phagemid. Structural genes are integral to packaging of DNA in to virus particles, and are supplied by the replication-defective Helper phage. The phagemid genome is extremely parasitic to the Helper phage. Ultimately, the PAAV particles are produced at yields that far surpass prior art systems;

[0133] FIG. 3 is a schematic representation of one embodiment of a phagemid genome (PAAV);

[0134] FIG. 4 shows the respective locations of f1 ori and pUC ori on the phagemid genome shown in FIG. 3;

[0135] FIG. 5 shows the location of a selection marker gene (AmpR) on a recombinant adeno-associated virus (rAAV) transgene cassette on the phagemid genome shown in FIG. 3;

[0136] FIG. 6 shows the rAAV transgene cassette on the phagemid genome shown in FIG. 3, which contains a gene of interest (e.g. GFP), the expression of which is driven by a CMV promoter and/or enhancer sequences, and tailed with a polyA signal. The entire transgene cassette is flanked by Inverted Terminal Repeat sequences (ITRs) from AAV;

[0137] FIG. 7 shows an embodiment of the Helper phage which is a bacteriophage engineered for rescuing phagemid particles from prokaryotic hosts carrying a phagemid genome, such as that shown in FIG. 3;

[0138] FIG. 8 shows a section of the genome of the helper phage shown in FIG. 5 comprising the RGD4C targeting peptide in the pIII minor coat protein;

[0139] FIG. 9 shows a first embodiment of a method for producing phagemid-AAV (PAAV) particles;

[0140] FIG. 10 shows a second embodiment of a method for producing phagemid-AAV (PAAV) particles;

[0141] FiG. 11 shows one embodiment of a phage-based approach for in vitro AAV production showing the three vectors, (i) phagemid-AAV (PAAV), (ii) Rep-Cap phagemid, and (iii) adenohelper phagemid;

[0142] FIG. 12 shows the genome map of an embodiment of the adenohelper phagemid vector shown in FIG. 11;

[0143] FIG. 13 shows the genome map of an embodiment of a Rep-Cap phagemid vector shown in FIG. 11;

[0144] FIG. 14 shows an embodiment of a unified adenohelper-Rep-cap phagemid-AAV (PAAV) vector;

[0145] FIG. 15 shows the genome map of an embodiment of the unified adenohelper-Rep-Cap phagemid vector shown in FIG. 11;

[0146] FIG. 16 shows an embodiment of in situ AAV production using either the three phagemid vectors shown in FIGS. 11-13, or the unified adenohelper-Rep-Cap-AAV phagemid vector shown in FIGS. 14 and 15;

[0147] FIG. 17 shows Transmission Electron Microscopy (TEM) of known AAVP vectors and PAAV vectors according to the invention. (A) RGD.AAVP.GFP filament (pink) is typically 1455.02 nm in length. (B) RGD. PAAV.GFP filament (blue) is typically 729.96 nm in length; helper phage present in virus sample (green) is typically 1186.03 nm in length;

[0148] FIG. 18 shows internalisation of known AAVP vectors and PAAV vectors according to the invention in: (A) 293AAV and (B) U87 cells after 2 and 4 hours. Flow cytometric analysis was used with gating threshold set at 20000 events of total cell population. (n=3)*=p<0.05, **=p<0.01;

[0149] FIG. 19 shows quantification of GFP-positive cells 9 days post-transduction in (A) 293AAV, (B) 293AAV with the addition of DEAE.DEXTRAN, (C) U87 and (D) U87 with the addition of DEAE.DEXTRAN. Flow cytometric analysis was used with gating threshold set at 20000 events of total cell population. (n=3)*=p<0.05, **=p<0.01;

[0150] FIG. 20 shows quantification of genome copy numbers of rAAV-GFP from cell lysates following phagemid-guided gene transfer (A) or transfection (B) of rAAV expression elements. (Experiment A: n=1; Experiment B: n=3);

[0151] FIG. 21 shows immunofluorescence staining of UW228 and DAOY human medulloblastoma cells to demonstrate expression of ?.sub.v, ?.sub.3 and ?.sub.5 integrin subunits, receptor for RGD4C-phagemid. Tumour cells were stained using primary rabbit anti-?.sub.v, ?.sub.3 or ?.sub.5 antibodies (diluted 1:50 in PBS-1%BSA), then with goat anti-rabbit AlexaFluor-488 secondary antibody (showed in green) and counterstained with 0.05 ?g/ml DAPI (in blue). Images were taken using a confocal microscope;

[0152] FIG. 22 shows targeted gene delivery to paediatric medulloblastoma cells by RGD4C-phagemid. Medulloblastoma cells (UW228) were grown on 96 well-plates, then transduced with RGD4C-phagemid vector carrying the Luciferase gene (RGD). Untreated cells or cells treated with the non-targeted vector (M13) were used as negative controls. Luciferase expression was monitored over a time course from day 2 to 4 after transduction;

[0153] FIG. 23 shows Western blot analyses showing down regulation of mTOR expression in paediatric UW228 and DAOY medulloblastoma cells following treatment with RGD4C-phagemid carrying the mTOR/shRNA (RGD4C-mTOR/shRNA)). Cell lysates were collected at day 4 post vector treatment, and total proteins were measured by BCA assay. Western blot was probed with a monoclonal antibody to human mTOR (Cell Signalling). Untreated cells (CTR) and cells treated with RGD4C-phagemid, lacking mTOR/shRNA, (RGD4C) were used as negative controls;

[0154] FIG. 24 shows combination treatment of temozolomide (TMZ) and RGD4C-phagemid carrying shRNA for mTOR in medulloblastoma. Medulloblastoma cells (UW228 and DAOY) were transduced with RGD4C-phagemid (RGD4C) or RGD4C-phagemid carrying mTOR/shRNA (RGD4C-mTOR/shRNA). Untreated cells were also used as controls. At day 7 post vector treatment, temozolmide (TMZ, 100 uM) was added in a few treated wells to assess effect of combination of vectors with chemotherapy. Images were taken at day 8 after vector treatment;

[0155] FIG. 25 shows treatment of medulloblastoma cells with TNF? vectors. UW228 cells were treated with RGD4C-phagemid-TNF? (RGD4C/TNF?) and non-targeted (ctr). A) Expression of TNF? in the medium of vector-treated cells, measured using human TNF? ELISA Max. B) Cell viability, using MTT assay, following expression of TNF?. Error bars: mean ?SEM;

[0156] FIG. 26 shows immunofluorescence staining of DIPG cells to demonstrate expression of ?.sub.v, ?.sub.3 and ?.sub.5 integrin subunits, receptor for RGD4C-phagemid. Cells were stained using primary rabbit antibodies then with goat anti-rabbit AlexaFluor-488 secondary antibody. Control cells received secondary antibody alone. Images were taken using a confocal microscope;

[0157] FIG. 27 shows selective and dose dependent delivery of gene expression to DIPG cells by RGD4C-phagemid/AAV. Increasing vector dose 1?10.sup.6 or 2?10.sup.6 TU/cell of RGD4C-phagemid-Luc (RGD4C) carrying the reporter Luc (luciferase) gene was used to treat DIPG cells. Luc expression was measured daily. Non-targeted vector lacking RGD4C (ctr) was used as negative control for targeting. Error bars: mean ?SEM;

[0158] FIG. 28 shows Treatment with RGD4C-phagemid-TNF?. DIPG cells were transduced with 2?10.sup.6 TU/cell RGD4C-phagemid-TNF? (RGD4C) and non-targeted vector as negative control (ctr). Apoptotic activity was measured at day 9 post-vector treatment using caspase-Glo assay (caspase 3/7, caspase 8, and caspase9). Error bars: mean ?SEM. *P?0.05, **P?0.01, ***P?0.001;

[0159] FIG. 29 shows luciferase expression after transduction with RGD.PAAV at various concentrations of transducing units;

[0160] FIG. 30 shows luciferase expression after transduction with NT.PAAV at various concentrations of transducing units; and

[0161] FIG. 31 shows the percentage of PAAV vectors bound to the cell surface of 293 AAV cells. RGD.PAAV vectors had 58.2% binding efficiency, whereas M13.PAAV vectors had 7.1% binding efficiency relative to their respective controls.

BACKGROUND

[0162] The development of gene delivery technology is instrumental to successful translation of basic research to the society. In the past decade, a number of viral and non-viral vectors have emerged as potential delivery vectors for industrial and therapeutic applications. An important property of vectors, in addition to being efficient at delivering genes, is that it must also be easily produced and commercially viable. In 2006, Hajitou et al. attempted to fulfil the need for such vectors by creating a hybrid between recombinant adeno-associated virus (rAAV) and filamentous bacteriophage (phage), called the Adeno-associated Virus/Phage (AAVP) (Nature protocols 2, 523-531(2007); Cell 125, 385-398 (2006)). The resulting AAVP vector possesses favourable characteristics of mammalian and prokaryotic viruses, but does not suffer from the disadvantages that those individual vectors normally carry. However, there are certain aspects of the AAVP vector that still leaves room for significant improvement. Above all, this includes the genetic design of the vector, which carries ramifications in its production and therapeutic properties. Ultimately, this leads to AAVP's relatively low gene transduction efficacy when compared to mammalian viruses.

[0163] The research described herein relates to the design of the most advanced version of phage gene delivery vectors and their superiority to the known and existing phage vector, AAVP, by using a so-called phagemid system, with the new phagemid vector being referred to as Phagemid/Adeno-associated Virion Phagemid (i.e. PAAV). Unlike the AAVP genome, which consists of a rAAV cassette inserted in to the filamentous phage genome, the PAAV genome does not contain any structural phage genesa prokaryotic helper virus is required to facilitate vector assembly (Mol Ther 3, 476-484; Pharmaceutical research 27, 400-420 (2010)). Separating the reproductive and therapeutic elements of the virus in to a therapeutic vector carrying the transgene and a separate helper virus carrying the structural genes substantially decreases the genome/vector size and thereby significantly increases transgene capacity, a useful advantage for gene therapy applications of the new system. Consequently, this results in the encapsidation of a eukaryotic virus genome into the capsid of a prokaryotic virus, resulting in a vector as hybrid between eukaryotic genome and prokaryotic capsid with enhanced production yield, gene transduction efficiency and flexibility of the vector system for other applications.

[0164] As described in the Examples below, the inventors have: [0165] 1. Designed and constructed a hybrid PhagemidAAV Vector (PAAV) particle expression system; [0166] 2. Characterised and determined whether the phagemid/AAV vector (PAAV) is more efficient at gene transduction than the known AAVP system at various stages, including but not limited to: [0167] a. Binding to the cell surface, [0168] b. Internalisation of the vector from the cell surface, [0169] c. Translocation of the vector genome to the host nuclei, and [0170] d. Recombinant transgene expression. [0171] 3. Determined whether the hybrid phagemid PAAVvector system is capable of producing rAAV from a mammalian producer cell-line.

[0172] Referring first to FIG. 1, there is shown a table comparing features of the phagemidAAV (PAAV) particles according to the invention (i.e. virions) with the prior art AAVP viral particles. As can be seen, the PAAV particles (6 kb) of the invention are much smaller than the known AAVP particles (14 kb), i.e. 42% less DNA, and 50% shorter viral particles, and the PAAV particles are produced at yields that far surpass prior art systems (100X) the yield of AAVP). As a result, PAAV particles of the invention can carry larger payloads, which is very useful for delivering multiple transgenes in gene therapy approaches. The inventors have therefore demonstrated that the modified bacteriophage expression system (PAAV) can be used as a highly viral vector for gene therapy, or for large-scale production of viral vectors.

EXAMPLE 1

PhagemidAAV Vector (PAAV) Construction

[0173] Referring to FIG. 2, there is shown an embodiment of a Helper Phage genome and a Phagemid genome (PAAV DNA) according to the invention, which are used together upon expression in a prokaryote to produce the phagemid-AAV (PAAV) particle, also shown in FIG. 1. Structural genes are integral to packaging of DNA in to virus particles, and are supplied by the replication-defective Helper phage, which is discussed in detail below. The phagemid genome is extremely parasitic to the Helper phage, meaning it outcompetes the replication-defective helper phage in both replication and packaging.

[0174] A) Phagemid/AAV Vector

[0175] Referring now to FIG. 3, there is shown one embodiment of the phagemid genome which is a plasmid containing two origins of replication and two other genetic elements. Phagemid genomes require two origins of replication to facilitate both its replication inside the prokaryotic (e.g. bacterial) host and packaging into phagemid particles when rescued by a helper virus.

[0176] Referring to FIG. 4, the first origin of replication (ori) is a high-copy number origin of replication (pUC ori that enables replication of the double-stranded phagemid (dsDNA) inside the prokaryotic host at large quantities. The second origin of replication is a phage origin of replication (f1 ori) that enables replication of the plasmid into single-stranded DNA, which can subsequently be packaged into a phagemid vector particle (PAAV).

[0177] Referring to FIG. 5, the phagemid genome includes a selection marker gene. In order for the phagemid genome to replicate efficiently inside the prokaryotic host, a selection marker (e.g. ampicillin resistance) is used to ensure expression and provides selective pressure to prevent loss of the phagemid genome in the form of an antibiotic resistance gene (with its own promoter). This ensures expression (and replication) of the phagemid genome when the prokaryotic host is cultured in the presence of the antibiotic that the selection marker confers resistance to.

[0178] Referring to FIG. 6, the phagemid genome further includes a recombinant (adeno-associated virus, AAV) transgene cassette which contains a transgene of interest. This can include, but is not limited to, polypeptides/proteins, short hairpin/small interfering/short guiding RNAs, or a combination of both. By way of example only, the transgene shown in FIG. 6 encodes GFP and human Beta-globin. Expression of the transgene is driven by a viral promoter (e.g. CMV) and/or enhancer sequences, and tailed with a polyA signal to prevent degradation. The promoter can also be a mammalian and tumour specific promoter in cancer gene therapy applications (i.e. promoter of the Glucose Regulated Protein [grp78]). The entire transgene cassette is flanked by Inverted Terminal Repeat sequences (ITRs) from AAV, which form a protective hairpin structure allowing the transgene cassette to be stably maintained as concatameric episomal (extra-chromosomal) DNA in the mammalian cell nucleus transduced by the phagemid particle. The ITRs enable AAV transgene cassettes to be stably expressed over a long period of time.

[0179] The phagemid, despite having a small genome, is unable to package itself into particles as it lacks structural phage genes. As a result, it requires rescuing by a helper virus, as shown in FIG. 7, which provides structural (i.e. capsid) proteins required for formation and extrusion of particles from the prokaryotic host. Conventionally speaking, genetic elements in the vector are generic and used widely in genetic engineering.

[0180] B) Helper Phage

[0181] Referring to FIG. 7, the helper phage (referred to herein as M13KO7) is a bacteriophage engineered specifically for rescuing phagemid particles (i.e. PAAV) from prokaryotic hosts carrying and/or containing the phagemid genome shown in FIG. 3. The helper phage contains a disrupted origin of replication (p15a, medium copy number) and packaging signal, which significantly deters its ability to package itself into phage particles. Consequently, the phagemid genome will outcompete the helper phage in both replication and packaging.

[0182] In order to give the phagemid targeting properties (or multifunctional properties as described in WO 2014/184528), the genome of the helper phage must be engineered to do so, as it provides the structural capsid proteins for phagemid particle assembly. For example, the helper genome may encode a pIII capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the resultant PAAVP particle to a desired target cell (e.g. tumour). It can also encode at least one pVIII capsid major coat protein that is configured to display a foreign peptide on the resultant PAAV particle. In one embodiment, therefore, it is desired to induce a 9-amino acid mutation in the pIII minor coat protein to confer specificity to angiogenic tumour cells and tumour endothelial cells that express ?.sub.v?.sub.3 and ?.sub.v?.sub.5 integrins. Thus, referring to FIG. 8, the genome of the helper phage comprises the RGD4C targeting peptide (CDCRGDCFCSEQ ID No: 7).

[0183] Once the PAAVP phagemid genome and the Helper phage have been constructed, they are used together to produce, in a prokaryotic host, the PhagemidAAV Vector (PAAV) particle, as discussed below.

EXAMPLE 2

PhagemidAAV Vector (PAAV) Production

[0184] The inventors have devised two different methods (Methods 1 and 2) for producing the PhagemidAAV Vector (PAAV) particle, and these are illustrated in FIGS. 9 and 10.

[0185] Notes:

[0186] TG1: a strain of E. coli that carries the fertility factor (F pilus).

[0187] 2xYT: liquid broth used to culture TG1 E. coli.

[0188] Kanamycin: antibiotic resistance selection marker present on the helper phage.

[0189] Ampicillin: antibiotic resistance selection marker present on the phagemid vector.

[0190] TYE top agar: solid media used to culture TG1 E. coli, adapted from 2x TY by the addition of 1.25% bacteriological agar.

[0191] Phagemid/AAV Vector (PAAV) Production Method 1: Infective Rescue

[0192] With Reference to FIG. 9: [0193] 1. Add 4-5 ml of TG1 E.coli carrying PAAV genome pre-culture (overnight) to 60 ml 2xYT (100 ?g/mL Ampicillin) supplemented with 1% glucose. [0194] 2. Incubate culture at 37? in shaker (250 RPM). [0195] 3. Once OD.sub.600 is in the range of 0.5 to 0.8 (log phase), add at least 1?10.sup.10 transducing units of helper phage (M13KO7) to culture. [0196] 4. Invert to mix. Incubate at 37? for 30 minutes. [0197] 5. Pour the infected starter culture from step 3 in to a 2 L flask with 2x YT (100 ?g/mL Ampicillin+25 ?g/mL Kanamycin) supplemented with 1% glucose to a final volume of 400-450 mL. [0198] 6. Incubate overnight in an orbital shaker at 37?, 250 rpm for 16-20 hours. [0199] 7. Purify phagemid (PAAV) particles from culture supernatant.

[0200] The benefits of Method 1 are its very high yields.

[0201] Phagemid/AAV Vector (PAAV) Production Method 2: Stable Producer Cell-Line

[0202] With Reference to FIG. 10:

[0203] Part 1: Competent Producer Cell-Line Production [0204] 1. Transform and plate TG1 competent E.coli (Zymo Research, USA) with ssDNA genome from helper hage M13KO7 in TYE top agar (50 ?g/mL Kanamycin) [0205] 1. Pick individual colonies and inoculate 5 mL 2xYT media (50 ?g/mL Kanamycin) supplemented with 1% glucose. [0206] 2. Incubate overnight in an orbital shaker at 37?, 250 rpm for 16-20 hours [0207] 3. Check for true positive transformants by extracting DNA from the 5 mL overnight cultures using a commercial extraction kit (QIAGEN, Netherlands) and run on 1% agarose gel (100 volts, 2.5 mA) against a DNA ladder. [0208] 4. Prepare chemically competent cells from the correct transformant identified in step 4 using a published protocol (adapted from that published by Krantz et al., UC Berkeley)

[0209] Part 2: PAAV Phagemid Particle Production [0210] 1. Transform competent cell-line created in Part 1 with a Phagemid/AAV genome and plate on TYE top agar (100 ?g/mL Ampicillin+50 ?g/mL Kanamycin) [0211] 2. Pick a colony and inoculate 5 mL 2xYT (100 ?g/mL Ampicillin+50 ?g/mL Kanamycin) supplemented with 1% glucose. [0212] 3. Incubate in an orbital shaker at 37?, 250 rpm for 4 hours [0213] 4. Pour the infected starter culture from step 3 in to a 2 L flask with 2xYT (100 ?g/mL Ampicillin+25 ?g/mL Kanamycin) supplemented with 1% glucose to a final volume of 400-450 mL [0214] 5. Incubate overnight in an orbital shaker at 37?, 250 rpm for 16-20 hours [0215] 6. Purify phagemid particles from culture supernatant

[0216] PAAV Phagemid Particle Purification [0217] 1. Transfer the warm overnight culture to centrifuge bottles and pellet the bacteria by centrifugation at 3300 G, 4? for 30 minutes. [0218] 2. Discard the pellet and transfer supernatant to a clean centrifuge bottle. [0219] 3. Add 30% volume of supernatant in each bottle with ice-cold 20% PEG-8000/2.5M NaCl and swirl to mix. [0220] 4. Incubate on ice for 4-24 hours [0221] 5. Precipitate phagemid particles by centrifugation at 100000 G, 4? for 30 minutes. Discard the supernatant. [0222] 6. Dry the phagemid particle pellet by centrifugation at 10000 G, 4? for 1 minute. [0223] 7. Remove remaining supernatant with PEG/NaCl [0224] 8. Resuspend the phagemid particle pellet in 0.5-2 mL PBS [0225] 9. Filter the resuspended phagemid particle preparation using a 0.45 micron filter. [0226] 10. Keep the preparation at 4?. The preparation is stable for up to 2 years 4?. A 25% glycerol stock can be stored indefinitely at ?80?.

EXAMPLE 3

Use of PhagemidAAV Vector (PAAV) for Gene Therapy Techniques

[0227] Examples 1 and 2 describe the components of the invention (i.e. phagemid genome shown in FIG. 3 and helper phage shown in FIG. 7) required to produce the PhagemidAAV Vector (PAAV) particle and two methods of production. Once produced and purified, the PAAV particles can have a range of uses, such as in gene therapy.

[0228] As an example, the PAAVP particles described herein carry the GFP transgene, as it is readily detectable in known assays to show successful delivery to a target cell. In therapy, any transgene may be selected and engineered into the phagemid genome shown in FIG. 3, to be carried in the resultant PAAV particles. For example, the transgene may be any gene encoding a protein, which may have therapeutic or industrial utility. For example, the transgene may encode dystrophin, a blood coagulation factor, insulin or a cytokine receptor sub-unit. The transgene may also encode a short hairpin/small interfering/short guiding RNA molecule using in RNAi therapy. The transgene may encode multiple polypeptides, nucleic acids, or a combination of both, fused together using an internal ribosomal entry site (IRES) or a viral fusion peptide (T2A peptides for in-frame fusion).

EXAMPLE 4

Use of PhagemidAAV Vector (PAAVP) for In Vitro AAV Production

[0229] In addition to gene therapy, the PAAVP particles described herein can be used in novel methods for producing adeno-associated virus (AAV). Phage-guided AAV production utilizes the ability of the phagemid particles to package large amounts of dsDNA. A typical AAV production system consists of three major elements: rAAV, rep-cap and adenohelper genes, which function together to production recombinant AAV particles. The inventors have devised two different strategies.

[0230] With reference to FIG. 11, the first strategy employed is to produce three different phagemid vectors that carry the rAAV-producing elements. These are the PhagemidAAV Vector (PAAV) (see FIG. 3), the adenohelper phagemid particle (see FIG. 12), and the rep-cap phagemid particle (see FIG. 13). The basic structures of these particles are similar, as they contain two origins of replication and a selection marker, as described in the phagemid/AAV construction section. The key difference, however, is the transgene cassette. While the PhagemidAAV (PAAV) genome contains an AAV transgene cassette, as shown in FIG. 3, the adenohelper and rep-cap particles contain the adenohelper transgene or rep-cap transgene, as shown in FIGS. 12 and 13, respectively.

[0231] In another embodiment, the inventors have genetically engineered a so-called unified construct that contains all of the required elements inside a single vector genome, as shown in FIGS. 14 and 15.

[0232] When introduced into the same mammalian producer cell (see FIGS. 11 and 14), either on separate vectors or on the same unified vector, the rep-cap and adenohelper genes behave as trans-acting elements that facilitate packaging of the rAAV genome in the phagemid/AAV vector. This production process is comparable to transient co-transfection of three plasmids. However, in this case, the plasmids are replaced with phagemid vectors carrying the very same elements.

[0233] Below is described a protocol for PAAVphagemid-guided production of adeno-associated virus (AAV).

[0234] Notes:

[0235] DMEM: Dulbecco's Modified Eagle Medium.

[0236] FBS: Foetal Bovine Serum, a growth supplement.

[0237] Complete media: DMEM+10% FBS.

[0238] EDTA: Ethyl-diamine tetra-acetic acid, an ion chelator used to dissociate cells by sequestering calcium ions required for tight junction formation.

[0239] GlutaMax: a growth supplement, analogue of L-Glutamine.

[0240] Protocol for Phagemid-Guided AAV Production:

[0241] 1. Seed and grow HEK293 cells in complete media (DMEM supplemented with 10% FBS, 20 mM GlutaMax, Penicillin/Streptomycin and Non-Essential Amino Acids) in a 15 cm tissue culture plate for a minimum of 48 hours until 80 % confluence is achieved.

[0242] 2. Mix Phagemid/AAV, rep-cap phagemid and adeno-helper phagemid to achieve a 1:1:1 transducing unit ratio under 5 mL total volume OR Aliquot a unified vector (single vector containing all three elements in a single particle) to achieve imillion transducing units per cell.

[0243] 3. Add an equal volume of serum-free DMEM (supplemented with 20 mM GlutaMax) to the transduction mixture made in step 3.

[0244] 4. Invert to mix. Incubate at room temperature for 15 minutes.

[0245] 5. Wash the HEK293 cells plated in step 1 with PBS, repeat 3 times.

[0246] 6. Add the transduction mixture and swirl gently to distribute the mixture evenly.

[0247] 7. Incubate at 37?, 5% CO2 in a cell culture incubator for 72 hours [0248] a. After 6 hours of incubation with the transduction mixture, supplement with an equal volume of complete media (DMEM supplemented with 10% FBS, 20 mM GlutaMax, Penicillin/Streptomycin and Non-Essential Amino Acids). [0249] b. After 24 hours, replace media with complete media (DMEM supplemented with 10% FBS, 20 mM GlutaMax, Penicillin/Streptomycin and Non-Essential Amino Acids).

[0250] rAAV Purification: [0251] 1. Add 0.5M EDTA solution to the medium in the tissue culture plate to a final concentration of 0.010M, incubate for 5 minutes at room temperature. [0252] 2. Collect the cells and media by aspiration and trituration and transfer to a 50 mL centrifuge tube. [0253] 3. Pellet the cells by centrifugation at 1500 RPM, 5 minutes, Room temperature. [0254] a. Optional: collect the supernatant for further AAV purification. [0255] 4. Resuspend the cell pellet in 2-5 mL serum-free DMEM. [0256] 5. Lyse the cells in the suspension by subjecting to 4 freeze-thaw cycles in an ethanol-dry ice bath and a water bath set to 37?. [0257] 6. Centrifuge the cell lysate at 10000 G, 10 minutes at Room temperature. [0258] a. Aliquot the supernatant for quantification/further purification/concentration. [0259] b. Discard the pellet (debris).

EXAMPLE 5

Use of PhagemidAAV Vector (PAAV) for In Situ AAV Production

[0260] Referring to FIG. 16, the inventors have devised a method for the in situ production of AAV particles using the PAAV.

[0261] Firstly, an optimal dose (or multiple doses) of the three phagemid vectors or the unified vector are introduced in vivo through intravenous/thecal/peritoneal or intramuscular/subcutaneous (or any of the aforementioned routes of administration). The diseased tissue is a tumour displaying the relevant integrins and so the targeting moiety on the phagemid PAAV particles is the RGD4C sequence. The tumour should start to produce rAAV containing the viral transgene encoded in the hybrid phagemid particle and not wild-type AAV. These AAV particles should autoinfect nearby sites, as they naturally have high affinity to mammalian tissue, and eradicate the tumour over a given time.

EXAMPLE 6

Engineering Pseudovirions for Large-scale Targeted Gene Transfer and Recombinant Adeno-Associated Virus Production

[0262] Transmission Electron Microscopy

[0263] In characterising the particles, the inventors imaged PAAV particles to show that vector size is substantially reduced when using the phagemid-based vector system. Using Transmission Electron Microscopy, the inventors imaged and measured the length of PAAV of the invention and known AAVP particles on mesh copper TEM grids after negative staining with uranyl acetate (see FIG. 17). It was found that the average AAVP particle was 1455.02 nm in length (FIG. 17A), while a typical PAAV particle according to the invention is only 729.96 nm in length (FIG. 17B)which equates to approximately 50% reduction in particle size. Compared to the helper phage that is used to produce PAAV particles (typically 1186.03 nm, FIG. 17B), the relative vector size is approximately 38% shorter than the helper virus.

[0264] The difference in vector size forms the basis of the theory that PAAV may be more efficient as a gene delivery vector than the AAVP, not only in terms of production yield, but also in subsequent infection processes when entering and expressing genes in mammalian cells. As such, the inventors probed vector efficiency at various stages of infection, including binding, internalisation, and gene expression in 293AAV (a derivative of Human Embryonic Kidney 293) and U87 glioblastoma cell lines.

[0265] Vector Internalisation

[0266] Following binding, vectors undergo receptor-mediated endocytosis by the target cell. To investigate potential differences in vector internalisation, the inventors assayed the number of internalised vectors in target cells at two time-points (2 hours, 2 H; 4 hours, 4 H) using flow cytometry (see FIG. 18). It was found that PAAV vectors were internalised more efficiently at 2 hours (Median Fluorescence Intensity (MFI)=1031.7, 335 higher than AAVP, p<0.05) and to a greater overall extent at 4 hours when compared to AAVP in both cell lines. The MFI at 2 hours for PAAV was significantly higher than AAVP by 335 for 293AAV and 207 for U87 cells (p<0.05). At 4 hours post-transduction, this difference became substantially greater for 293AAV (829 MFI, p<0.05), but less so for U87 (157 MFI, non-significant). Overall, the MFI peaked at 2092 (293AAV, p<0.05, FIG. 18A) and 1137 (U87, FIG. 18B) for PAAV1-treated cells, which was significantly higher than AAVP, which respectively peaked at 1063 (293AAV) and 980 (U87). The data demonstrates that PAAV performed consistently better than AAVP in rate and extent of internalisation for both time-points in both cell-lines.

[0267] Green Fluorescent Protein Expression following AAVP and PAAV-Mediated Gene Transfer

[0268] To investigate whether the differences in vector internalisation translates to increased gene expression, the inventors performed a GFP-expression assay using RGD and NT PAAV.GFP and AAVP.GFP vectors (see FIG. 19). In this experiment, they also tested whether addition of the cationic polymer DEAE.DEXTRAN (Dex) could enhance gene transfer by increasing the bioavailability and endosome-escape of PAAVvectors, as described in WO2014/184529. Nine days post-transduction, cells were trypsinised, and counted and analysed using a flow cytometer. It was found that transgene expression was generally higher in 293AAV cells than U87, regardless of whether Dex was used to assist vector transduction. When vector alone is used, the targeted RGD.PAAV.GFP vector transduces target cells with higher efficacy (7.7%, p<0.01 and 1.4%, p<0.05 GFP+ve cells in 293AAV and U87 cells, respectively)compared to AAVP, this translates to a 2.44 and 1.56 fold increase respectively in 293AAV and U87 cells (FIG. 19A, C).

[0269] When Dex is added however, gene expression increases dramatically for RGD.AAVP and RGD.PAAV vectors. In 293AAV cells, GFP expression in RGD.AAVP.GFP treated cells increased to 25% while RGD. PAAV.GFP treated cells experience a substantial increase to 50% (all p<0.01); addition of Dex resulted in an increase in gene expression of 7.9-fold for RGD.AAVP and 6.5-fold for RGD.PAAVP (FIG. 19B, D). In U87 cells, which is regarded as highly resilient to transduction, Dex was able to augment gene expression by over 3.6-fold in RGD.PAAV.GFP to 4.8% GFP+ve cells (p<0.01)this was not the case for RGD.PAAV.GFP, as Dex increased gene expression by only 1.5-fold to 1.3% GFP+ve cells (p<0.05). Interestingly, Dex enabled transduction by NT. PAAV (non-targeted) vectors in 293AAV cells (7.34%), but not with U87.

[0270] Phagemid-Guided Recombinant Adeno-Associated Virus Production

[0271] To assess whether PAAV and phagemid-derived vectors could be used to produce rAAV in a commercial producer cell-line, the inventors transduced 293AAV cells with three targeted vectors, which are normally plasmids that require transfection for gene transfer. They were able to harvest rAAV particles from the cell lysate and quantify the rAAV gene copy number (GC) per mL over three time-points after phagemid-guided transduction (FIG. 20A). When compared to conventional transfection with FuGene6 (transfection reagent, 3.99e11 GC/mL, FIG. 20B), phagemid-guided rAAV production provides over 1.9-fold increase at 168 hours (7.69e11 GC/mL, FIG. 21A) in rAAV yield. Because phagemid-guided gene transfer requires extensive intracellular processing (unlike transfection), it requires a longer time for viral genes to be expressed and packaged in to functional particles. When yields are compared at the same 72-hour time-point however, transfection produced 1.76e11 GC/mL higher than phage-guided rAAV production. The rAAV yield per mL culture supernatant from transfection or phagemid-guided production dishes at all time points were approx. 8-9e10 GC/mL with no observable trends (data not shown).

EXAMPLE 7

Construction and Uses of RGD4C-Phagemid

[0272] The tripeptide, RGD, is found in proteins of the extracellular matrix, including fibronectin. The integrins act as receptors for fibronectin by binding to the RGD motif located in fibronectin in the site of cell attachment to ?.sub.v?.sub.3 integrin, and so the inventors induced a 9-amino acid mutation in the pIII minor coat protein of the recombinant phagemid particle in order to confer its specificity to tumour cells and angiogenic tumour-associated endothelial cells that express ?.sub.v?.sub.3 and ?.sub.v?.sub.5 integrins. Thus, the genome of the second vector comprises the RGD.sub.4C targeting peptide (CDCRGDCFCSEQ ID No: 7).

[0273] Referring to FIG. 21, there is shown immunofluorescence staining of UW228 and DAOY human medulloblastoma cells, which demonstrates the expression of ?.sub.v, ?.sub.3 and ?.sub.5 integrin subunits, receptor for RGD4C-phagemid. These data demonstrate that the phagemid vector containing the RGD4C targeting peptide can be used for targeted gene delivery and gene therapy in the paediatric brain tumor, medulloblastoma.

[0274] Referring to FIG. 22, there is shown targeted gene delivery to paediatric medulloblastoma cells by the RGD4C-phagemid, over a time course of 4 days. The data show that RGD4C-phagemid mediated efficient and selective gene delivery that increased overtime in medulloblastoma.

[0275] FIG. 23 shows Western blot analyses showing down-regulation of the mammalian target of rapamycin (mTOR) expression in paediatric UW228 and DAOY medulloblastoma cells following treatment with RGD4C-phagemid carrying the mTOR/shRNA (RGD4C-mTOR/shRNA)). These data demonstrate that the RGD4C-phagemid can be successfully used to deliver shRNA in tumor cells to knock down expression of the therapeutic target mTOR in a selective and efficient way.

[0276] FIG. 24 shows combination treatment of temozolomide (TMZ) and RGD4C-phagemid carrying shRNA for mTOR in medulloblastoma cells, known for their resistance to temozolomide. The data demonstrate that targeted the RGD4C-mTOR/shRNA can re-sensitize medulloblastoma cells to TMZ and achieve complete tumor cell eradication. Therefore, targeted knockdown of mTOR expression by the RGD4C-phagemid is an efficient strategy to use in combination with temozolomide against chemoresistant tumor cells, such as medulloblastoma.

[0277] FIG. 25 shows treatment of medulloblastoma cells with TNF? vectors. Therefore, RGD4C/TNF? has therapeutic potential for use in targeted tumor killing such as medulloblastoma. FIG. 26 shows immunofluorescence staining of DIPG cells to demonstrate expression of ?.sub.v, ?.sub.3 and ?.sub.5 integrin subunits, receptor for RGD4C-phagemid. These data demonstrate that the phagemid vector containing the RGD4C targeting peptide can be used for targeted gene delivery and gene therapy in the paediatric brain tumors, DIPG.

[0278] FIG. 27 shows selective and dose dependent delivery of gene expression to DIPG cells by RGD4C-phagemid/AAV. These data prove that RGD4C-phagemid can successfully deliver gene expression to DIPG in a dose-dependent and selective way. FIG. 28 shows treatment with RGD4C-phagemid-TNF?. These data demonstrate that RGD4C-phagemid can successfully deliver TNF? to DIPG in a selective manner, resulting in apoptosis induction. Therefore, RGD4C-phagemid-TNF? has therapeutic potential for use in targeted therapy against DIPG.

EXAMPLE 8

Luciferase Expression of RGD4C-Phagemid

[0279] Protocol:

[0280] HEK cells were plated in a 48-well plate in complete media (DMEM, 10% FCS, 1% glutamine, 1% penicillin/streptomycin) and incubated for at least 48 hours until 70-80% confluence was reached. Cells were then washed with PBS and transduced with hybrid phage/phagemid vectors suspended in serum-free media (DMEM) for 12 hours before the media was supplemented with complete media. Luciferase expression was measured by adding 10 uL of culture media to 50 uL of prepared Quanti-luc (InvivoGen, USA) reagent. The emission of photos was measured using a plate reader equipped with a luminometer (promega, USA).

[0281] FIG. 29 shows luciferase expression after transduction with RGD.PAAV at various concentrations of transducing units, and FIG. 30 shows luciferase expression after transduction with NT.PAAV at various concentrations of transducing units. The graphs demonstrate a dose-dependent exponential relationship between time and expression of luciferase after incubation with hybrid phage/phagemid vectors at various concentrations. The figures demonstrate that quantifiable gene expression can be achieved by phagemid vectors via an assay for secreted luciferase.

EXAMPLE 9

Binding of RGD.PAAV Vector to 293 AAV Cells

[0282] Protocol:

[0283] 293AAV cells were seeded on 24-well plates in complete media (DMEM +10%FCS, 1%Glutamine, 1% Penicillin/Streptomycin), and were left to reach 70-90% confluence for a minimum of 48 hours. The cells were washed twice with 500 uL PBS and placed on ice before being transduced with 200000 TU/cell (transducing units/cell) of PAAV vectors suspended in 200 uL of serum-free DMEM. After 1 hour of incubation on ice, the media was recovered from the wells and the amount of phagemid particles were titrated on TG1 E.coli and quantified by colony-counting.

[0284] Referring to FIG. 31, there is shown the percentage of PAAV vectors bound to the cell surface of 293 AAV cells. RGD.PAAV vectors had 58.2% binding efficiency, whereas M13. PAAV vectors had 7.1% binding efficiency relative to their respective controls.

[0285] Discussion There is strong evidence to suggest that targeted PAAV vectors are more efficient than AAVP vectors at gene transduction in both commercial and disease cell lines. Both internalisation and gene expression data concordantly indicate that PAAV are more efficient than AAVP. Evidence is also provided to suggest a strong synergistic effect between Dex and PAAV vectors on gene transduction that surpasses that of AAVP. Although these data suggest that PAAV are superior to AAVP, it must also be considered that PAAV vector samples contain helper phage contamination. Despite efforts in optimising experimental conditions during vector production, helper phage contamination (in this case, approx. 1/10) is unavoidable and will competitively inhibit transduction as it too displays the RGD targeting sequence on its minor coat protein. Taking this into account, the internalisation and gene expression data may very well be underestimating the true efficacy of RGD.PAAV. Additionally, because the internalisation assay utilises staining of intracellular phage capsid for signal detection, the smaller overall size (and available capsid protein per particle) of the PAAV means that the proportional number of particles internalised cannot be compared directly to that of AAVP, which we have shown using TEM is twice in length compared to PAAV particles. Accordingly, methods of the invention involve a purification step (e.g. FPLC) to remove the helper phage.

[0286] It is essential that in addition to providing mechanistic insight, future work must encompass replication of all experiments using pure PAAV samples. In particular, phagemid-guided rAAV production may benefit greatly from decreased competitive inhibition by helper phage contamination and yield multiple fold higher rAAV particles compared to conventional transfection protocols.

[0287] Summary

[0288] Large-scale production of recombinant adeno-associated virus (rAAV) has been a major hurdle for research, development and commercialization of genetic therapy. Despite being well-researched, rAAV production has been restricted to laboratory scales due to scalability limitations. By far, transient transfection of producer cells has been the most popular technique, yielding high-purity rAAV vectors with no infectious contaminants, despite being extremely costly. Thus, an alternative method for gene transfer in rAAV-production systems is greatly warranted.

[0289] Hybrid phagemid vectors that are highly efficient at gene transfer to mammalian cells are described. By combining a rAAV transgene cassette to the phage capsid, it is possible to create a vector system that is easily produced at commercial scales. These phagemid/AAV (PAAV) vectors have very large cloning capacities and are targeted to mammalian cells, meaning transfection reagents are not required. As it is possible to clone all genetic elements for AAV production in to single or multiple phagemid vectors, the inventors have developed this platform technology for large-scale rAAV production. A novel large-scale rAAV production system using PAAV and bacteriophage vectors has been developed, in both adherent cells and in cell-suspensions. This platform technology will enable commercial virus production for clinical translation at

[0290] GMP standards and pave the way for commercial production of other biosynthetics.